Clozapine and Treatment-Resistant Schizophrenia: Prescribing Patterns at a Neuropsychiatric Hospital in the City of Buenos Aires
DOI:
https://doi.org/10.53680/vertex.v37i173.1062Keywords:
schizophrenia, treatment-resistant schizophrenia, clozapine, prescribing delay, polypharmacyAbstract
Objective: Despite being a highly effective drug for treatment-resistant schizophrenia (TRS), clozapine remains underutilized. This study aims to evaluate clozapine prescribing patterns in outpatients from a specialized psychiatric hospital in Argentina. Methods: This retrospective, observational, cross-sectional study included adult patients with a diagnosis of schizophrenia receiving outpatient treatment at our institution. Data were collected by reviewing medical records from November 2024 to January 2025. Statistical analyses included descriptive statistics, paired t-tests, Pearson's correlations, and multiple regression. Results: The sample included 199 patients with a mean age of 36 years (SD: 6.6). A total of 75.4% were receiving concomitant medication; prior use of long-acting injectable antipsychotics (LAIs) was low (8%), while antipsychotic polypharmacy was frequent (30.6%). The mean time from schizophrenia diagnosis to clozapine initiation was greater than five years (266.47 weeks, SD: 270.4), with a mean of 3.17 adequate prior antipsychotic trials (SD: 1.53). Hospitalizations significantly decreased after clozapine initiation (mean change: 1.74, SD: 1.14; large effect size, d = 1.09). Conclusions: Our findings indicate that clozapine continues to be underutilized in our setting and highlight the importance of earlier initiation to reduce hospitalization rates and improve clinical outcomes.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Julieta Ramírez, María Delfina Tavella, Adrián Cabrera, Germán Weisbrot, Guillermo J. Hönig; Daniel Martínez; Nora S. Crespi, Ricardo Corral

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.